多西紫杉醇联合放疗用于中晚期鼻咽癌的疗效观察

摘要

Objective:To observe the actual efficacy of paclitaxel combined with radiotherapy for advanced nasopharyngeal carcinoma patients, and to evaluate its clinical value. Methods: 42 patients with advanced nasopharyngeal carcinoma were divided into the observe group (21 cases, docetaxel combination with radiotherapy treatment),and the control group (21 cases,radiotherapy treatment) in which effective rate and 5-year survival rate were compared in two groups . Results: The clinical improvement of the observation group was significantly better than that in control group. The effective rate and 5-year survival rate were statistically significant (P<0.05) between two groups. Conclusion: The docetaxel combined with radiotherapy for the treatment of advanced nasopharyngeal carcinoma has a significant effect,safe and reliable, and be worthy of clinical application.%目的：观察多西紫杉醇联合放疗用于中晚期鼻咽癌的实际疗效，评价其临床应用价值。方法：回顾性分析42例中晚期鼻咽癌患者，按照治疗方式分为观察组21例，采用多西紫杉醇联合放疗进行治疗；以及对照组21例，采用单纯放疗进行治疗；比较两组患者治疗有效率及5年生存率。结果：应用多西紫杉醇联合放疗治疗的观察组临床改善明显优于对照组，治疗有效率及5年生存率组间差异均具有统计学意义（P＜0.05）。结论：多西紫杉醇联合放疗用于中晚期鼻咽癌的治疗，具有疗效显著，安全可靠的特点，值得临床推广应用。